These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31544312)

  • 1. XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant.
    Persaud AK; Li J; Johnson JA; Seligson N; Sborov DW; Duah E; Cho YK; Wang D; Phelps MA; Hofmeister CC; Poi MJ
    Mol Carcinog; 2019 Dec; 58(12):2327-2339. PubMed ID: 31544312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.
    Voorhees PM; Usmani SZ
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):719-28. PubMed ID: 27673290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome.
    Dimopoulos MA; Souliotis VL; Anagnostopoulos A; Papadimitriou C; Sfikakis PP
    J Clin Oncol; 2005 Jul; 23(19):4381-9. PubMed ID: 15883412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells.
    Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma.
    Giglia JL; White MJ; Hart AJ; Toro JJ; Freytes CO; Holt CC; Cai Y; Williams SM; Brandt SJ
    Biol Blood Marrow Transplant; 2014 Jul; 20(7):1014-20. PubMed ID: 24704384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma.
    Gul Z; Bashir Q; Cremer M; Yusuf SW; Gunaydin H; Arora S; Slone S; Nieto Y; Sherwani N; Parmar S; Shah N; Dinh YT; Hosing CM; Popat UR; Kebriaei P; Shpall EJ; Giralt SA; Champlin RE; Qazilbash MH
    Leuk Lymphoma; 2015 Feb; 56(2):533-5. PubMed ID: 24882259
    [No Abstract]   [Full Text] [Related]  

  • 7. Genetic variants in DNA repair pathways are not associated with disease progression among multiple myeloma patients.
    Thyagarajan B; Arora M; Guan W; Barcelo H; Jackson S; Kumar S; Gertz M
    Leuk Res; 2013 Nov; 37(11):1527-31. PubMed ID: 24129343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous transplantation and maintenance therapy in multiple myeloma.
    Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
    N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
    Mai EK; Benner A; Bertsch U; Brossart P; Hänel A; Kunzmann V; Naumann R; Neben K; Egerer G; Ho AD; Hillengass J; Raab MS; Neubauer A; Peyn A; Ko YD; Peter N; Scheid C; Goldschmidt H
    Br J Haematol; 2016 Jun; 173(5):731-41. PubMed ID: 26990892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma.
    Dimopoulos MA; Souliotis VL; Anagnostopoulos A; Bamia C; Pouli A; Baltadakis I; Terpos E; Kyrtopoulos SA; Sfikakis PP
    Haematologica; 2007 Nov; 92(11):1505-12. PubMed ID: 18024399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant.
    Poi MJ; Li J; Sborov DW; VanGundy Z; Cho YK; Lamprecht M; Pichiorri F; Phelps MA; Hofmeister CC
    Mol Carcinog; 2017 Jul; 56(7):1722-1732. PubMed ID: 28150872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
    Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
    Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
    J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure.
    Souliotis VL; Dimopoulos MA; Episkopou HG; Kyrtopoulos SA; Sfikakis PP
    DNA Repair (Amst); 2006 Aug; 5(8):972-85. PubMed ID: 16781199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma.
    Wichert S; Pettersson Å; Hellmark T; Johansson Å; Hansson M
    Exp Hematol; 2016 May; 44(5):342-351.e5. PubMed ID: 26774385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.
    Nath CE; Trotman J; Tiley C; Presgrave P; Joshua D; Kerridge I; Kwan YL; Gurney H; McLachlan AJ; Earl JW; Nivison-Smith I; Zeng L; Shaw PJ
    Br J Clin Pharmacol; 2016 Jul; 82(1):149-59. PubMed ID: 26879446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melphalan 140 mg/m
    Auner HW; Iacobelli S; Sbianchi G; Knol-Bout C; Blaise D; Russell NH; Apperley JF; Pohlreich D; Browne PV; Kobbe G; Isaksson C; Lenhoff S; Scheid C; Touzeau C; Jantunen E; Anagnostopoulos A; Yakoub-Agha I; Tanase A; Schaap N; Wiktor-Jedrzejczak W; Krejci M; Schönland SO; Morris C; Garderet L; Kröger N
    Haematologica; 2018 Mar; 103(3):514-521. PubMed ID: 29217776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous stem cell transplantation for multiple myeloma: Long-term results.
    Kumar L; Boya RR; Pai R; Harish P; Mookerjee A; Sainath B; Patekar MB; Sahoo RK; Malik PS; Sharma OD; Gupta R
    Natl Med J India; 2016; 29(4):192-199. PubMed ID: 28050994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.